Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9349878 | 1.00 | SRD5A1 (0.72) | SRD5A1SRD5A2 | |
| SCHEMBL4187755 | 1.00 | SRD5A1 (0.72) | SRD5A1SRD5A2 | |
| SCHEMBL8021083 | 1.00 | SRD5A1 (0.72) | SRD5A1SRD5A2 | |
| SCHEMBL13604091 | 1.00 | SRD5A1 (0.72) | SRD5A1SRD5A2 | |
| SCHEMBL8724807 | 0.92 | SRD5A1 (0.71) | SRD5A1SRD5A2 | |
| SCHEMBL9571051 | 0.90 | SRD5A1 (0.72) | SRD5A1SRD5A2 | |
| SCHEMBL13604098 | 0.90 | SRD5A1 (0.72) | SRD5A1SRD5A2 | |
| SCHEMBL2376048 | 0.90 | SRD5A1 (0.72) | SRD5A1SRD5A2 | |
| SCHEMBL11424034 | 0.89 | SRD5A1 (0.71) | SRD5A1SRD5A2 | |
| SCHEMBL11424038 | 0.89 | SRD5A1 (0.71) | SRD5A1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625920-B2 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090082320-A1 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2009-03-26 | — | — | US | disclosed |
| US-20070088042-A1 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | MEISSNER ROBERT S | 2007-04-19 | — | — | US | disclosed |
| US-7186838-B2 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20050165039-A1 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2005-07-28 | — | — | US | disclosed |
| EP-1485095-A1 | FLUORINATED 4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003077919-A1 | FLUORINATED 4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-09-25 | — | — | WO | disclosed |
| EP-0664812-B1 | 17-BETA-ARYL ESTER CARBOXYLATES OF 4-AZA-5-ALPHA-ANDROSTANE-3-ONES | MERCK & CO INC (US) | 2000-01-05 | — | — | EP | disclosed |
| EP-0538192-B1 | New 17-beta-substituted aza-androstanderivatives | CIBA GEIGY AG (CH) | 1997-04-23 | — | — | EP | disclosed |
| EP-0484094-B1 | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | SANKYO CO (JP) | 1996-06-26 | — | — | EP | disclosed |
| US-5302621-A | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | SANKYO COMPANY, LIMITED (JP) | 1994-04-12 | — | — | US | disclosed |
| US-5278159-A | Steroid enzyme inhibitor | MERCK & CO., INC. (US) | 1994-01-11 | — | — | US | disclosed |
| EP-0538192-A1 | New 17-beta-substituted aza-androstanderivatives | CIBA-GEIGY AG (CH) | 1993-04-21 | — | — | EP | disclosed |
| US-5155107-A | Inhibiting androgen action, anticarcinogenic agents, treating skin disorders, baldness | FARMITALIA CARLO ERBA (IT) | 1992-10-13 | — | — | US | disclosed |
| EP-0484094-A2 | Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use | Sankyo Company Limited (JP) | 1992-05-06 | — | — | EP | disclosed |
| EP-0468012-A1 | 17-g(b)-SUBSTITUTED-4-AZA-5-g(a)-ANDROSTAN-3-ONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION. | ERBA CARLO SPA (IT) | 1992-01-29 | — | — | EP | disclosed |
| WO-1991012261-A1 | 17β-SUBSTITUTED-4-AZA-5α-ANDROSTAN-3-ONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | FARMITALIA CARLO ERBA S.R.L. (IT) | 1991-08-22 | — | — | WO | disclosed |
| US-4845104-A | Oxidized analogs of 17β-N-monosubstituted-carbamoyl-4-aza-5-α-androstan-3-ones | MERCK & CO., INC. (US) | 1989-07-04 | — | — | US | disclosed |
| EP-0271220-A1 | Oxidized analogs of 17 beta-N-monosubstituted carbamoyl-4-aza 5 alpha-androst-1-en-3-ones | MERCK & CO. INC. (US) | 1988-06-15 | — | — | EP | disclosed |
| US-4220775-A | Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors | MERCK & CO., INC. (US) | 1980-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165039-A1 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | FSHR, AR, NR5A1 | SRD5A1 8/4885SRD5A2 12/4885 |
| US-20070088042-A1 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | FSHR, AR, NR5A1 | SRD5A1 8/4885SRD5A2 12/4885 |
| US-20090082320-A1 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | FSHR, AR, NR5A1 | SRD5A1 8/4885SRD5A2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.